JP2019507721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507721A5 JP2019507721A5 JP2018528588A JP2018528588A JP2019507721A5 JP 2019507721 A5 JP2019507721 A5 JP 2019507721A5 JP 2018528588 A JP2018528588 A JP 2018528588A JP 2018528588 A JP2018528588 A JP 2018528588A JP 2019507721 A5 JP2019507721 A5 JP 2019507721A5
- Authority
- JP
- Japan
- Prior art keywords
- idh1
- mutation
- composition
- ras
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SDYPYTQPBOKFBU-QQXFXQEMSA-N CC/C=C(\C=C(/N)\N([C@@H](CC1)[NH+](N([C@H](C(NC(C2)CC2(F)F)=O)c2ccccc2Cl)C(CN=C2)=C=C2F)[O-])C1=O)/C#N Chemical compound CC/C=C(\C=C(/N)\N([C@@H](CC1)[NH+](N([C@H](C(NC(C2)CC2(F)F)=O)c2ccccc2Cl)C(CN=C2)=C=C2F)[O-])C1=O)/C#N SDYPYTQPBOKFBU-QQXFXQEMSA-N 0.000 description 1
- ZRRBGUOZDZSRFF-NBTWKBOSSA-N N#CC(C1)=CC=NC1N([C@@H](CC1)C(N([C@H](C(CCC(C2)CC2(F)F)=O)c2ccccc2Cl)c2cc(F)cnc2)=O)C1=O Chemical compound N#CC(C1)=CC=NC1N([C@@H](CC1)C(N([C@H](C(CCC(C2)CC2(F)F)=O)c2ccccc2Cl)c2cc(F)cnc2)=O)C1=O ZRRBGUOZDZSRFF-NBTWKBOSSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021089138A JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263580P | 2015-12-04 | 2015-12-04 | |
| US62/263,580 | 2015-12-04 | ||
| US201662300721P | 2016-02-26 | 2016-02-26 | |
| US62/300,721 | 2016-02-26 | ||
| PCT/US2016/064832 WO2017096309A1 (en) | 2015-12-04 | 2016-12-02 | Methods of treatment of malignacies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021089138A Division JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507721A JP2019507721A (ja) | 2019-03-22 |
| JP2019507721A5 true JP2019507721A5 (enExample) | 2020-01-16 |
| JP6892448B2 JP6892448B2 (ja) | 2021-06-23 |
Family
ID=57610403
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528588A Expired - Fee Related JP6892448B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性腫瘍の処置の方法 |
| JP2018528735A Active JP6852073B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性病変を処置する方法 |
| JP2021038684A Pending JP2021098740A (ja) | 2015-12-04 | 2021-03-10 | 悪性病変を処置する方法 |
| JP2021089138A Withdrawn JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528735A Active JP6852073B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性病変を処置する方法 |
| JP2021038684A Pending JP2021098740A (ja) | 2015-12-04 | 2021-03-10 | 悪性病変を処置する方法 |
| JP2021089138A Withdrawn JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200268726A1 (enExample) |
| EP (2) | EP3383433A1 (enExample) |
| JP (4) | JP6892448B2 (enExample) |
| KR (2) | KR20180086255A (enExample) |
| CN (1) | CN108883184A (enExample) |
| AU (2) | AU2016363011B2 (enExample) |
| CA (2) | CA3007363A1 (enExample) |
| ES (1) | ES2905915T3 (enExample) |
| IL (4) | IL299563A (enExample) |
| MA (1) | MA43374A (enExample) |
| MX (2) | MX391229B (enExample) |
| WO (2) | WO2017096309A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| PH12021551647A1 (en) | 2014-03-14 | 2022-06-06 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds |
| KR20170057411A (ko) | 2014-09-29 | 2017-05-24 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 활성 화합물 및 이들의 사용 방법 |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| ES2897959T3 (es) | 2015-10-15 | 2022-03-03 | Servier Lab | Terapia de combinación para tratar neoplasias malignas |
| CA3002029A1 (en) | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| IL311873A (en) | 2015-10-15 | 2024-06-01 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| KR20250126877A (ko) | 2015-10-15 | 2025-08-25 | 르 라보레또레 쎄르비에르 | 악성 종양의 치료를 위한 조합물 요법 |
| EP3509570A1 (en) | 2016-09-07 | 2019-07-17 | Celgene Corporation | Tablet compositions |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| US20210196701A1 (en) | 2018-05-16 | 2021-07-01 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US11013733B2 (en) * | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11311527B2 (en) * | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| EP3886840A4 (en) * | 2018-11-30 | 2022-08-24 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| KR20220101148A (ko) | 2019-11-14 | 2022-07-19 | 셀진 코포레이션 | 암의 치료를 위한 소아용 제제 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| US20230084515A1 (en) * | 2020-02-19 | 2023-03-16 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
| CN115968292A (zh) * | 2020-07-24 | 2023-04-14 | 隆萨本德公司 | 含乙酸的api过饱和溶液的喷雾干燥 |
| WO2024229332A1 (en) * | 2023-05-03 | 2024-11-07 | Memorial Sloan-Kettering Cancer Center | Anti-cancer treatments and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| KR101893112B1 (ko) | 2012-01-06 | 2018-08-30 | 아지오스 파마슈티컬스 아이엔씨. | 치료학적으로 활성인 화합물 및 이의 이용 방법 |
| US9474779B2 (en) * | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| AU2013232379A1 (en) * | 2012-03-12 | 2014-09-25 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
| PE20160744A1 (es) | 2013-07-11 | 2016-08-01 | Agios Pharmaceuticals Inc | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| CA2842635A1 (en) * | 2014-01-20 | 2015-07-20 | University Health Network | Pre-cancerous cells and their identification in the prevention and treatment of cancer |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| PH12021551647A1 (en) * | 2014-03-14 | 2022-06-06 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds |
| US20170007661A1 (en) | 2014-03-14 | 2017-01-12 | Agios Pharmaceuticals, Inc | Pharmaceutical compositions of therapeutically active compounds |
| KR20170057411A (ko) | 2014-09-29 | 2017-05-24 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 활성 화합물 및 이들의 사용 방법 |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
-
2016
- 2016-12-02 CA CA3007363A patent/CA3007363A1/en active Pending
- 2016-12-02 WO PCT/US2016/064832 patent/WO2017096309A1/en not_active Ceased
- 2016-12-02 CN CN201680080463.0A patent/CN108883184A/zh active Pending
- 2016-12-02 MX MX2018006745A patent/MX391229B/es unknown
- 2016-12-02 AU AU2016363011A patent/AU2016363011B2/en not_active Ceased
- 2016-12-02 MA MA043374A patent/MA43374A/fr unknown
- 2016-12-02 KR KR1020187018928A patent/KR20180086255A/ko not_active Ceased
- 2016-12-02 EP EP16816817.7A patent/EP3383433A1/en not_active Withdrawn
- 2016-12-02 MX MX2018006831A patent/MX380596B/es unknown
- 2016-12-02 IL IL299563A patent/IL299563A/en unknown
- 2016-12-02 KR KR1020187019185A patent/KR102924995B1/ko active Active
- 2016-12-02 AU AU2016362425A patent/AU2016362425B2/en active Active
- 2016-12-02 IL IL298663A patent/IL298663A/en unknown
- 2016-12-02 CA CA3007218A patent/CA3007218A1/en not_active Abandoned
- 2016-12-02 US US15/781,019 patent/US20200268726A1/en not_active Abandoned
- 2016-12-02 EP EP16816809.4A patent/EP3383400B1/en active Active
- 2016-12-02 WO PCT/US2016/064600 patent/WO2017096150A1/en not_active Ceased
- 2016-12-02 JP JP2018528588A patent/JP6892448B2/ja not_active Expired - Fee Related
- 2016-12-02 ES ES16816809T patent/ES2905915T3/es active Active
- 2016-12-02 US US15/368,439 patent/US10188656B2/en active Active
- 2016-12-02 JP JP2018528735A patent/JP6852073B2/ja active Active
-
2018
- 2018-06-03 IL IL259783A patent/IL259783A/en unknown
- 2018-06-03 IL IL259787A patent/IL259787A/en unknown
-
2021
- 2021-03-10 JP JP2021038684A patent/JP2021098740A/ja active Pending
- 2021-05-12 US US17/318,606 patent/US20220000878A1/en not_active Abandoned
- 2021-05-27 JP JP2021089138A patent/JP2021121636A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507721A5 (enExample) | ||
| JP2019502669A5 (enExample) | ||
| JP2021098740A5 (enExample) | ||
| JP2018535951A5 (enExample) | ||
| Prelaj et al. | Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program | |
| Tan et al. | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer | |
| JP2018536636A5 (enExample) | ||
| JP2019533670A5 (enExample) | ||
| JP2019532051A5 (enExample) | ||
| JP2019513694A5 (enExample) | ||
| Sundar et al. | Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers | |
| Wilson et al. | Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma | |
| JP2020514311A5 (enExample) | ||
| JP2014523516A5 (enExample) | ||
| Wang et al. | Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers | |
| Oza et al. | Homologous recombination repair deficiency as a therapeutic target in sarcoma | |
| JP2018526376A5 (enExample) | ||
| JP2017508805A5 (enExample) | ||
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| FI3362065T3 (fi) | Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi | |
| JP2018534288A5 (enExample) | ||
| Wells Jr et al. | Update: the status of clinical trials with kinase inhibitors in thyroid cancer | |
| JP2016512831A5 (enExample) | ||
| Ettrich et al. | Regorafenib | |
| JP2019506392A5 (enExample) |